Urolithin A

Urolithin A is a gut microbiome-derived metabolite recognized as one of the most potent known activators of mitophagy, the cellular process of clearing damaged mitochondria to restore energy and muscle function. Because most people's gut bacteria cannot reliably produce it from food, direct supplementation has become the primary way researchers and consumers access consistent doses. This guide covers the mechanisms, evidence, dosing, and safety in depth.

Quick Facts

• Category: Gut microbiome-derived metabolite, mitophagy activator
• Also known as: UA, 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one
• Most-studied form: Direct urolithin A supplementation
• Key benefit: The most potent known activator of mitophagy, the cellular process of clearing damaged mitochondria to restore energy and muscle function

What Is Urolithin A?

Urolithin A is a postbiotic metabolite, a compound gut bacteria produce when they break down ellagitannins and ellagic acid from foods like pomegranates, walnuts, and certain berries. A critical limitation is that only about 30 to 40% of people have the gut microbiome composition needed to produce meaningful urolithin A from food alone. The remaining 60 to 70% can eat pomegranates and walnuts without ever creating significant urolithin A in their bodies, regardless of diet consistency. This microbiome variability is a key reason direct supplementation is studied as an alternative.

Urolithin A gained attention in longevity research following discoveries from the Auwerx lab at EPFL, the same laboratory that pioneered key NAD+ and nicotinamide riboside research. It represents one of the more notable compounds to emerge from microbiome science in the past decade.

Urolithin A activates mitophagy, a cellular self-cleaning process. Mitochondria function as cells' power plants, and over time these power plants accumulate damage. Instead of working efficiently, damaged mitochondria pump out excessive free radicals, drain energy, and are thought to accelerate aging. Mitophagy is the body's quality-control system: it identifies mitochondria with compromised membranes (signs of dysfunction), tags them, and removes them through a recycling process, making room for healthy, efficient new mitochondria to take over.

Forms & Bioavailability

How Urolithin A Reaches the Cells

Urolithin A from food (the gut-produced pathway) requires pomegranate, walnut, and berry ellagitannins to travel through the digestive tract, where specific bacterial strains metabolize them into urolithin A. This pathway is highly unpredictable: research shows only about 40% of people meaningfully convert dietary ellagitannins to urolithin A, and circulating levels in producers range from 0.2 to 20 micromolar, representing extreme individual variability.

Direct urolithin A supplementation bypasses this microbiome variability, providing a consistent dose regardless of an individual's bacterial composition. Mitopure, a branded and clinically validated form developed by Timeline Therapeutics (now Amazentis), was used in the landmark ATLAS trial (2022) and subsequent immune studies at 500 to 1000mg doses, the doses that showed the most pronounced benefits in published research. Generic urolithin A is bioavailable and absorbed well, but lacks the extensive clinical dataset that Mitopure carries.

Mechanisms of Action

Primary Mechanism: PINK1/Parkin-Mediated Mitophagy

The PINK1/Parkin pathway is the cell's damaged-mitochondria detection system. When a mitochondrion loses its inner membrane potential, a sign of damage, the PINK1 protein accumulates on its outer membrane, acting as a distress signal. PINK1 then recruits Parkin, an enzyme that tags the damaged mitochondrion with ubiquitin, marking it for destruction. The tagged mitochondrion gets engulfed by an autophagosome and recycled. Urolithin A amplifies this process by increasing the expression of both PINK1 and Parkin, ensuring damaged mitochondria are swiftly identified and removed before they can cause oxidative damage to surrounding cells.

Secondary Mechanisms

Urolithin A activates AMPK, the cell's metabolic master switch, which senses low energy and triggers cleanup processes, reinforcing the mitophagy signal and broadly promoting cellular maintenance over growth. It also inhibits mTOR, which normally suppresses autophagy under nutrient-rich conditions, shifting the cell into maintenance mode and allowing autophagy (including mitophagy) to proceed unimpeded. Urolithin A reduces mitochondrial reactive oxygen species (ROS) production, since damaged mitochondria leak excessive ROS that damage surrounding cellular components. It also suppresses NF-kB, a pro-inflammatory signaling pathway, reducing systemic inflammation and age-related immune dysregulation. In aged muscle, urolithin A improves the efficiency of protein synthesis, which is critical for maintaining muscle mass with age.

The Mitochondrial Renewal Cycle

Urolithin A is often studied alongside NAD+ precursor compounds, which boost NAD+ and drive mitochondrial biogenesis (the creation of new mitochondria) via the SIRT1/PGC-1 alpha pathway. Urolithin A instead activates mitophagy, the removal of old, damaged mitochondria. Together, the two mechanisms complete the mitochondrial renewal cycle: NAD+ precursors help build new, healthy mitochondria, while urolithin A helps remove old, damaged ones, resulting in more complete mitochondrial rejuvenation at the cellular level than either mechanism alone.

Evidence-Based Benefits

Mitophagy activation and mitochondrial quality control. Evidence level: Established. Human muscle biopsy studies confirm urolithin A directly activates mitophagy in skeletal muscle. Researchers have observed the cellular markers of active mitophagy (LC3-II conversion, p62 degradation, PINK1/Parkin activation) in human muscle tissue following urolithin A supplementation. This is the mechanistic foundation for all downstream benefits.

Muscle strength and endurance in older adults. Evidence level: Established. The ATLAS trial (Singh et al., 2022) randomized 88 middle-aged adults to 500mg, 1000mg, or placebo urolithin A daily for 16 weeks. Hamstring leg strength improved approximately 12% versus placebo at both doses, peak oxygen consumption (VO2 max) improved, 6-minute walk test performance improved, acylcarnitine levels (a mitochondrial efficiency marker) decreased significantly, and C-reactive protein (an inflammation marker) decreased. This is the gold-standard human trial demonstrating urolithin A's impact on muscle aging.

Reduction of inflammatory markers. Evidence level: Promising. Multiple human and animal studies show urolithin A reduces pro-inflammatory cytokines (IL-6, TNF-alpha, CRP). A 2025 randomized trial published in Nature Aging found urolithin A (1000mg daily) significantly reduced age-associated immune dysfunction markers in middle-aged adults, expanding naive CD8+ T cells (which decline with age) and improving immune cell metabolic capacity.

Exercise performance and recovery. Evidence level: Promising. The ATLAS trial showed aerobic endurance improvements, and animal models demonstrate urolithin A enhances endurance exercise capacity and reduces exercise-induced muscle damage. PINK1/Parkin activation in muscle promotes faster mitochondrial turnover, removing the ROS-leaking mitochondria that would otherwise impair recovery. Human exercise studies beyond ATLAS are ongoing.

Longevity signaling and the aging process. Evidence level: Promising to established in model organisms. Urolithin A is among the few compounds that activates multiple longevity pathways simultaneously (AMPK, SIRT1, mTOR inhibition, mitophagy). Animal models show consistent lifespan extension in yeast, C. elegans, and mice, sometimes exceeding 40% lifespan gains. While human lifespan data will take decades to establish, the fundamental aging pathways urolithin A targets are conserved across species, suggesting translatable benefit.

Cognitive health and neurodegeneration. Evidence level: Emerging. Animal models and early human mechanistic studies are promising. A 2024 study in Alzheimer's & Dementia found urolithin A improved cognition and restored mitophagy in Alzheimer's disease models. Mitochondrial dysfunction is implicated in Parkinson's, Alzheimer's, and cognitive decline, and a large 650-participant clinical study examining brain health outcomes is expected to report results in 2026.

Cardiovascular health and endothelial function. Evidence level: Emerging. A 2025 iScience study showed urolithin A improves cardiovascular biomarkers and endothelial function through PINK1/Parkin-mediated mitophagy in blood vessels. Healthy mitochondria in endothelial cells maintain vascular function, and while this is early-stage evidence, it is mechanistically sound.

Gut health and microbiome. Evidence level: Emerging. Direct supplementation with urolithin A produces circulating and fecal levels sufficient to shift microbiome composition, a prebiotic-like effect. Early studies suggest it may reshape microbial communities toward beneficial taxa, potentially creating a feedback loop that supports natural urolithin A production over time.

Dosage & Timing

Timing and Administration

Urolithin A can be taken in the morning, afternoon, or evening, as its absorption is not meal-dependent and it absorbs consistently with or without food. Mitophagy is a cumulative, continuous process, so daily consistency drives the most benefit; this is not a compound suited to occasional use. Piperine (from black pepper extract) is studied for enhancing bioavailability of polyphenols and may increase urolithin A absorption.

How to Maximize Absorption

• No need to time around meals. Urolithin A absorbs efficiently with or without meals.
• Consider piperine enhancement. Piperine (from black pepper extract) increases polyphenol bioavailability broadly and may amplify urolithin A's tissue penetration.
• Use consistent dosing. Taking the same dose at the same time daily maintains steady-state circulating levels, optimizing continuous mitophagy signaling.
• Combine with exercise. Endurance and resistance training activate overlapping mitophagy pathways (AMPK, SIRT1). Combining urolithin A with exercise is studied for multiplying benefits.
• Manage caloric intake. A mild caloric deficit or intermittent fasting enhances AMPK signaling, synergizing with urolithin A's mTOR inhibition.
• Prioritize sleep. Much mitochondrial recycling happens during sleep, so 7 to 9 hours nightly supports mitophagy's work.

Synergies: Compounds That Work With Urolithin A

NAD+ Precursor Compounds (e.g. Nicotinamide Riboside)

These two mechanisms work on opposite ends of the mitochondrial lifecycle. NAD+ precursors raise NAD+, activating SIRT1/PGC-1 alpha and mitochondrial biogenesis (building new mitochondria), while urolithin A activates PINK1/Parkin-mediated mitophagy (removing old mitochondria). A NAD+ precursor without a mitophagy activator can lead to accumulation of new mitochondria alongside old damaged ones; a mitophagy activator without a biogenesis driver provides efficient removal but without compensatory new mitochondrial production. Together, they are studied as a more complete mitochondrial renewal system.

Fisetin

Fisetin is a senolytic, clearing senescent cells (cells that are alive but no longer functioning). Urolithin A clears damaged mitochondria within cells. Together, they target cellular debris at two levels: damaged organelles (urolithin A) and dysfunctional cells (fisetin), offering complementary cleanup mechanisms.

Spermidine

Spermidine induces autophagy broadly, the cellular recycling system that encompasses mitophagy as a specialized form. Urolithin A drives selective mitophagy, specifically targeting damaged mitochondria. Spermidine's broader autophagy promotion may enhance the cleanup environment that urolithin A operates within.

Trans-Resveratrol

Resveratrol activates SIRT1, and urolithin A also works partly through SIRT1/AMPK. These are complementary pathways rather than redundant ones, with both compounds engaging the same beneficial pathway from slightly different angles, often studied together for potentially amplified benefits.

Magnesium

Magnesium is a cofactor for ATP production and cellular energy metabolism. Healthy mitochondrial function, which urolithin A promotes, depends on adequate magnesium status.

CoQ10 (Ubiquinol)

CoQ10 is embedded in the inner mitochondrial membrane, where it shuttles electrons in the energy production chain. Urolithin A clears dysfunctional mitochondria that can't perform this function efficiently; together, removing damaged mitochondria while fueling the ones that remain represents a complementary approach to mitochondrial support.

Interactions & Contraindications

mTOR Pathway Considerations

Urolithin A inhibits mTOR. Patients on immunosuppressive medications that target mTOR (such as sirolimus or everolimus) should consult their physician before supplementing, as the effects could be additive.

Cancer Treatment Interaction (Theoretical)

mTOR inhibition is sometimes used in cancer therapy. Urolithin A should not be taken concurrently with mTOR-targeting cancer treatments without medical supervision, as the additive effect is unknown.

Cytochrome P450 Metabolism

Urolithin A undergoes glucuronidation and sulfation (Phase II metabolism) but does not significantly induce or inhibit CYP3A4, CYP2D6, or other major metabolic enzymes, so interaction risk with standard medications is low.

Populations Requiring Caution

Immunosuppressed individuals should note that urolithin A enhances immune function (expanding naive CD8+ cells, improving NK cell counts) and should discuss supplementation with their physician. Organ transplant recipients, who often use mTOR inhibitors to prevent rejection, should seek medical consultation before use. Those with documented pomegranate allergies, since urolithin A is derived from pomegranate ellagitannins, should avoid it. There is no human safety data for pregnancy and lactation, so avoiding use during these periods is prudent pending further research.

Safety, Side Effects & Warnings

Urolithin A has a strong safety profile across human clinical trials to date. Twenty-eight and 90-day toxicity studies found no alterations in clinical parameters, blood chemistry, hematology, or target organ identification, and the compound is not genotoxic. The ATLAS trial (2022) enrolled 88 subjects over 16 weeks at 500 to 1000mg daily with zero serious adverse events and no abnormalities in liver function, kidney function, hematological parameters, or ECG. A 2025 immune trial enrolled 50 subjects at 1000mg daily for 4 weeks with no serious adverse events reported.

Reported Side Effects

Side effects are rare and mild. The most common are occasional muscle aches (myalgia), headaches, or mild GI discomfort, reported in under 5% of trial participants and typically resolving within days. All reported effects were classified as possibly or probably related rather than definitively caused by urolithin A.

Who Benefits Most From Urolithin A

Urolithin A deficiency isn't deficiency in the traditional sense, like vitamin D deficiency. It's better described as a metabolic capability gap. About 60 to 70% of adults lack the specific gut bacteria required to convert dietary ellagitannins (from pomegranates, walnuts, berries, nuts) into urolithin A, regardless of how often they eat these foods.

The Three Urolithin Metabotypes

Researchers have identified three distinct phenotypes. Metatype A, good converters, make up about 40% of the population and harbor bacterial strains capable of multi-step ellagitannin metabolism, efficiently producing urolithin A after pomegranate or walnut consumption. Metatype B, partial converters, make up about 30% of the population and produce urolithin B or other urolithin metabolites, but not urolithin A specifically. Metatype 0, non-converters, make up about 30% of the population and lack the bacterial capacity to convert ellagitannins into any urolithin, meaning eating pomegranates produces no urolithin A in their bodies.

This is not a dietary choice; it's a microbial composition difference largely determined by bacterial inheritance (microbiome seeded early in life through delivery method, early-life antibiotics, and family environment). By taking urolithin A as a direct supplement, metatypes B and 0 (roughly 60% of the population) can access this compound without depending on bacterial conversion.

Frequently Asked Questions

What exactly is mitophagy and why does it matter?

Mitophagy is selective autophagy, cellular recycling targeted specifically at mitochondria. Mitochondria function as cells' power plants, but over time they accumulate damage (oxidative damage, lipid peroxidation, protein damage). Damaged mitochondria leak free radicals and produce less ATP (energy). Mitophagy identifies these worn-out power plants, recycles them, and makes room for new, healthy ones. Mitochondrial dysfunction is implicated in aging, muscle loss, cognitive decline, metabolic disease, and reduced energy, and urolithin A directly activates this cleanup process.

Can I just eat pomegranates instead of supplementing?

Only if you're one of the roughly 40% of people whose gut bacteria can convert pomegranate ellagitannins into urolithin A. Research shows that about 60% of people eating pomegranates produce little to no urolithin A in their bodies, regardless of frequency. It's not about diet discipline; it's about microbial composition, which is largely fixed. Direct supplementation ensures consistent urolithin A intake regardless of metatype.

How long before I notice results?

Mitophagy is a cellular-level process that accumulates over weeks. Muscle strength improvements in the ATLAS trial became statistically significant after 12 to 16 weeks. Some people report improved energy or exercise recovery within 4 to 6 weeks, but individual variation is high. The real benefits accrue over months as damaged mitochondria are systematically cleared and replaced with healthy ones.

What's the difference between Mitopure and generic urolithin A?

Mitopure is the branded, patented form developed by Timeline Therapeutics (acquired by Amazentis). It's the form used in published clinical trials (ATLAS, MitoImmune, etc.). Generic urolithin A is bioavailable and should work similarly, but it hasn't been extensively tested in human clinical trials under its own name. Mitopure comes with clinical safety and efficacy data, while generic urolithin A offers potential cost savings but with less clinical backing behind that specific product.

Should I take it daily or just on certain days?

Daily and consistently is the typical recommendation. Mitophagy is an ongoing cellular maintenance process, and taking urolithin A regularly maintains steady-state activation of the PINK1/Parkin pathway and mTOR inhibition. Sporadic dosing would provide sporadic benefit.

Is urolithin A safe long-term?

Based on current data, evidence is reassuring but not yet complete. Human clinical trials have documented safety through approximately 6 months of continuous use, and long-term (1+ year) human data are limited. Animal models show safety at equivalent doses over multiple years, and published toxicity assessments found no genotoxicity, no organ toxicity, and no serious adverse events across tested dose ranges. Larger, longer-duration human trials would further strengthen this conclusion.

Can athletes use urolithin A?

Yes, and it may offer particular benefit. Exercise activates many of the same pathways urolithin A targets (AMPK, mitophagy), so the combination of endurance or resistance training with urolithin A supplementation may produce compounding benefits. The ATLAS trial included middle-aged adults and showed improvements in both strength and aerobic capacity. Endurance athletes especially may be of research interest, since endurance training is fundamentally a mitochondrial adaptation.

Are there any warnings or contraindications I should know about?

Urolithin A warrants caution if you're on mTOR-targeting immunosuppressants or cancer therapies (consult your physician). It should be avoided if pregnant, nursing, or if you have documented pomegranate allergies. Those with certain autoimmune conditions managed with immunosuppression should check with their doctor due to urolithin A's immune-stimulating effects. Otherwise, for healthy adults, the safety profile is favorable.

Scientific References

1. Singh, A., D'Amico, D., Andreux, P. A., et al. "Urolithin A Improves Muscle Strength, Exercise Performance, and Biomarkers of Mitochondrial Health in a Randomized Trial in Middle-Aged Adults." Cell Reports Medicine, 2022;3(5):100633.
2. "Effect of the Mitophagy Inducer Urolithin A on Age-Related Immune Decline: A Randomized, Placebo-Controlled Trial." Nature Aging, 2025.
3. Ryu, D., Moullan, N., Theou, O., et al. "Urolithin A Induces Mitophagy and Prolongs Lifespan in C. Elegans and Increases Muscle Function in Rodents." Nature Medicine, 2016;22(8):879-888.
4. "Direct Supplementation With Urolithin A Overcomes Limitations of Dietary Exposure and Gut Microbiome Variability." European Journal of Clinical Nutrition, 2021;75(6):945-952.
5. Andreux, P. A., Blanco-Bose, W., Ryu, D., et al. "The Mitophagy Activator Urolithin A Is Safe and Induces a Marker of Mitophagy in Humans." Nature Metabolism, 2019;1(6):595-603.
6. Liu, Z., Tian, Z., Wang, M., et al. "Emerging Evidence of Urolithin A in Sports Nutrition: Bridging Preclinical Findings to Athletic Applications." Frontiers in Nutrition, 2024;12:1585922.
7. "Safety Assessment of Urolithin A, a Metabolite Produced by the Human Gut Microbiota Upon Dietary Intake of Plant Derived Ellagitannins and Ellagic Acid." Food and Chemical Toxicology, 2017;108:289-297.
8. Leonov, A., Arlia-Ciommo, A., Piano, A., et al. "Longevity Extension by Pbp1/SGT1 Overexpression in Yeast Depends on Sirtuins and Ties to Centromeric and Telomeric Gene Silencing Pathways." Cell Reports, 2015;7(5):1624-1635.
9. Pellegrino, D., Teixeira, A. M., Verhoeven, V., Vandenput, L. "Pharmacological Effects of Urolithin A and Its Role in Muscle Aging." Journals of Gerontology Series A, 2024;79(2):glad022.
10. Hou, Y., Wei, Y., Lautrup, S., de Cabo, R. "Urolithin A Improves Alzheimer's Disease Cognition and Restores Mitophagy and Lysosomal Functions." Alzheimer's & Dementia, 2024;20(7):4829-4844.
11. "Urolithin A Provides Cardioprotection and Mitochondrial Quality Enhancement." iScience, 2025.
12. "Biological Significance of Urolithins, the Gut Microbial Ellagic Acid-Derived Metabolites: The Evidence So Far." Evidence-Based Complementary and Alternative Medicine, 2013;2013:270418.
13. Espin, J. C., Larrosa, M., Garcia-Conesa, M. T., Tomas-Barberan, F. "Biological Significance of Urolithins, the Gut Microbial Ellagic Acid-Derived Metabolites: The Evidence So Far." Journal of Agricultural and Food Chemistry, 2013;61(48):11736-11742.
14. Lamuel-Raventos, A., Onclinx, C. "Targeting Aging With Urolithin A in Humans: A Systematic Review." Ageing Research Reviews, 2024;101553.

Disclaimer

This article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It does not constitute medical advice and is independent of any specific product or brand. Always consult a qualified healthcare provider before beginning any new supplement regimen, particularly if you are pregnant, breastfeeding, taking medications, or managing a medical condition.